A peripheral signature of Alzheimer's disease featuring microbiota-gut-brain axis markersOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study tested whether gut microbiota and blood mediators of the microbiota-gut-brain axis are associated with the amyloid cascade in sporadic Alzheimer's disease (AD). It integrated three systems in one cohort. The fecal microbiome was profiled by 16S rRNA sequencing. Blood mediators included the bacterial product LPS, cell adhesion molecules, and pro- and anti-inflammatory cytokines. The amyloid cascade was measured with amyloid PET, plasma pTau-181, and neurofilament light chain (NfL). Spearman correlation matrices linked the three systems.
Who was studied?
The cohort was 85 community-dwelling Italians aged 50 to 85 years, drawn from the INDIA-FBP amyloid imaging study. Amyloid PET status classified participants. There were 34 patients with cognitive impairment due to AD (CI-AD), 37 with cognitive impairment not due to AD (CI-NAD), and 13 cognitively unimpaired persons (CU). None had taken antibiotics or anti-inflammatory drugs in the prior three months. All donated stool and blood samples for analysis.
What were the most important findings?
CI-AD patients showed higher abundance of Clostridia UCG-014 and decreased Moryella and Blautia (p less than 0.04). They had elevated LPS (p less than 0.03) and upregulated adhesion molecules. Pro-inflammatory IL1beta, IL6, and TNFalpha rose while anti-inflammatory IL10 fell in CI-AD (p less than 0.05). Brain amyloid, plasma pTau-181, and NfL were all increased (p less than 0.004). CI-NAD showed different shifts, including higher Collinsella and increased NfL. Critically, immune and endothelial mediators were widely associated with amyloid cascade markers only in CI-AD, not CI-NAD.
What are the greatest implications of this study?
The findings suggest a peripheral signature of Alzheimer's disease that combines gut microbiota shifts, blood LPS, vascular inflammation, and endothelial damage. These mediators tracked with amyloid, tau, and neurodegeneration specifically in AD. The pattern supports a model where increased intestinal permeability lets bacterial products reach the bloodstream and possibly the brain, offering candidate biomarkers and treatment targets. The study was small, observational, and cross-sectional, using non-parametric correlations. The authors stress it cannot establish whether microbiota changes precede or follow brain pathology.